We used vilazodone for these experiments because unlike some other SSRI vilazodone does not inhibit CYP2D6, which is required for the conversion of the breast cancer pro-drug tamoxifen into its active metabolite endoxifen, nor does it affect CYP3A4 activity, which metabolizes many chemotherapeutics [32]. Here, CYP3A4 is linked to breast carcinoma.